Ferroptosis and prostate cancer: A translational path from molecular mechanisms to precision therapy - PubMed
4 hours ago
- #Ferroptosis
- #Prostate Cancer
- #Precision Therapy
- Castration-resistant prostate cancer poses a clinical challenge with resistance to therapies and limited efficacy.
- Ferroptosis is an iron-dependent cell death driven by lipid peroxidation, with therapeutic potential through GPX4 inhibition, glutathione depletion, or iron overload using compounds like RSL3 and Erastin.
- It shows promise in overcoming drug resistance and enabling synergistic effects with anti-androgen therapy, chemotherapy, and immunotherapy.
- The review summarizes ferroptosis regulatory networks in prostate cancer, including PI3K-AKT-mTOR, Hippo/YAP, and PGE2 pathways.
- It covers combination treatment strategies, clinical trial progress, and proposes a translational framework of 'ferroptosis regulatory network-biomarkers-precision therapy'.
- Challenges include drug resistance, targeting accuracy, and clinical translation, aiming to accelerate biomarker discovery and multimodal combination regimens.